• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate

Search Results

filter by

Disease

diseases

article type

news type

event

event type

topic

topic type

location

location-search

date

date range filter – slider
1999 — 2025

DNDi 2025 Projects of the Year recognize contributions of DNDi teams and partners working to deliver urgently needed innovations for people affected by Chagas disease and river blindness

DNDi's 2025 Projects of the Year are Biomarkers for Chagas disease and emodepside for river blindness.
  • 3 Oct 2025
  • News

DNDi 2025 Projects of the Year recognize contributions of DNDi teams and partners working to deliver urgently needed innovations for people affected by Chagas disease and river blindness

DNDi's 2025 Projects of the Year are Biomarkers for Chagas disease and emodepside for river blindness.
  • 3 Oct 2025
  • News

New regimens of benznidazole for the treatment of chronic Chagas disease in adult participants in indeterminate form or with mild cardiac progression (NuestroBen study): protocol for a phase III randomised, multicentre non-inferiority clinical trial

BMJ Open

  • 30 Sep 2025
  • Scientific articles

New regimens of benznidazole for the treatment of chronic Chagas disease in adult participants in indeterminate form or with mild cardiac progression (NuestroBen study): protocol for a phase III randomised, multicentre non-inferiority clinical trial

  • 30 Sep 2025
  • Scientific articles

Performance evaluation of rapid diagnostic tests for Chagas disease in Jutiapa, Guatemala

Journal of the Brazilian Society of Tropical Medicine

  • 29 Sep 2025
  • Scientific articles

Performance evaluation of rapid diagnostic tests for Chagas disease in Jutiapa, Guatemala

  • 29 Sep 2025
  • Scientific articles

Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trials

The Lancet Microbe

  • 8 Sep 2025
  • Scientific articles

Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trials

  • 8 Sep 2025
  • Scientific articles

Collaborative synthesis for neglected diseases through the Open Synthesis Network: structure–activity relationships of arylaminopyrazoles as Chagas disease treatments

ACS Infectious Diseases

  • 11 Aug 2025
  • Scientific articles

Collaborative synthesis for neglected diseases through the Open Synthesis Network: structure–activity relationships of arylaminopyrazoles as Chagas disease treatments

  • 11 Aug 2025
  • Scientific articles

AN2 Therapeutics and DNDi collaborate on clinical development of promising new oral compound to treat chronic Chagas disease

DNDi will share extensive clinical trial network and expertise to rapidly advance the clinical development of AN2’s oral drug candidate AN2-502998, which has curative potential for chronic Chagas disease. Startup activities are underway for a Phase I first-in-human study for oral AN2-502998, with a Phase II study initiation planned for 2026.
  • 23 Jul 2025
  • Press releases
PaedsFilm2024-ValleduparColombia-202409-22

AN2 Therapeutics and DNDi collaborate on clinical development of promising new oral compound to treat chronic Chagas disease

DNDi will share extensive clinical trial network and expertise to rapidly advance the clinical development of AN2’s oral drug candidate AN2-502998, which has curative potential for chronic Chagas disease. Startup activities are underway for a Phase I first-in-human study for oral AN2-502998, with a Phase II study initiation planned for 2026.
  • 23 Jul 2025
  • Press releases
PaedsFilm2024-ValleduparColombia-202409-22

América Latina combate el auge de la transmisión del chagas de madre a hijo

El País

  • 18 Jul 2025
  • In the media
El Pais logo

América Latina combate el auge de la transmisión del chagas de madre a hijo

  • 18 Jul 2025
  • In the media
El Pais logo

Antitrypanosomal quinazolines targeting lysyl-tRNA synthetase show partial efficacy in a mouse model of acute Chagas disease

Science Translational Medicine

  • 9 Jul 2025
  • Scientific articles

Antitrypanosomal quinazolines targeting lysyl-tRNA synthetase show partial efficacy in a mouse model of acute Chagas disease

  • 9 Jul 2025
  • Scientific articles

¿Qué es la enfermedad de chagas? Habla hombre que resucitó tras padecerla

Los Informantes

  • 26 Jun 2025
  • In the media
los-informantes-logo

¿Qué es la enfermedad de chagas? Habla hombre que resucitó tras padecerla

  • 26 Jun 2025
  • In the media
los-informantes-logo

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

New technical guidelines from Colombia's National Institute of Health based on research supported by DNDi will enable earlier treatment of Chagas disease nationwide.

New technical guidelines from Colombia's National Institute of Health based on research supported by DNDi will enable earlier treatment of Chagas disease nationwide.

  • 5 Jun 2025
  • Press releases
Chagas-Colombia-RapidTests-202505-01

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

New technical guidelines from Colombia's National Institute of Health based on research supported by DNDi will enable earlier treatment of Chagas disease nationwide.

New technical guidelines from Colombia's National Institute of Health based on research supported by DNDi will enable earlier treatment of Chagas disease nationwide.

  • 5 Jun 2025
  • Press releases
Chagas-Colombia-RapidTests-202505-01

Please select a search term or criteria.

loading
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license